Opus Genetics (IRD) risk factors, FY2024 10-K

Risks Related to the Opus Acquisition

1. 01The integration with Former Opus presents challenges, and the failure to successfully integrate the businesses could have a material adverse effect on our business, financial condition and results of operations
2. 02potential unknown liabilities and unforeseen increased expenses, delays or regulatory conditions associated with the Opus Acquisition
3. 03After the Opus Acquisition, we significantly expanded our product pipeline and business operations and shifted our business strategies, and these changes may not result in an improvement in the value of our common stock
4. 04If our stockholders do not approve the conversion of our Series A Preferred Stock at the 2025 Annual Meeting of Stockholders, we may be required to divert funds from our business to pay dividends on outstanding shares of Series A Preferred Stock

Risks Related to the Development of Our Gene Therapy Products and other Product Candidates

1. 05Our gene therapy product candidates are based on a novel technology, which makes it difficult to predict the time and cost of development and of subsequently obtaining regulatory approval
2. 06Gene therapies are novel, complex and difficult to manufacture. We could experience production problems in our network of external facilities that result in delays in our development or commercialization programs or otherwise adversely affect our business
3. 07Any of these events could prevent us from achieving or maintaining market acceptance of any products for which we receive marketing approval and could significantly harm our business, financial condition, results of operations and prospects
4. 08We received Orphan Drug Designation in September 2024 and Rare Pediatric Disease Designation in August 2024 for OPGx-LCA5 to treat LCA5, an early-onset retinal degeneration that causes vision loss. We may, in the future, apply for such designations for our other gene therapy product candidates in the United States
5. 09We may encounter substantial delays in our planned clinical trials, or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities
6. 10changes in regulatory requirements and guidance that require amending or submitting new clinical protocols
7. 11We may be negatively impacted if the results of our planned clinical trials are inconclusive or if there are safety concerns or serious adverse events associated with our product candidates
8. 12The results of previous clinical trials may not be predictive of future results, and the results of our current and planned clinical trials may not satisfy the requirements of the FDA
9. 13If we experience delays or difficulties in the enrollment of patients in clinical trials, our ability to conduct and complete those clinical trials, and our ability to seek and receive necessary regulatory approvals, could be delayed or prevented
10. 14proximity and availability of clinical trial sites for prospective patients
11. 15Changes in regulatory requirements or FDA guidance, or unanticipated events during our clinical trials, may result in changes to clinical trial protocols or additional clinical trial requirements, which could result in increased costs to us or delays in development timelines
12. 16We may expend a substantial amount of our resources to pursue a particular indication and fail to capitalize on indications that may be more profitable or for which there is a greater likelihood of success

Risks related to the Commercialization of RYZUMVI and Product Candidates which Obtain Marketing Approval

1. 17We depend heavily on the success of our product pipeline. If we fail to find strategic partners or we (including our strategic partner) fail to adequately commercialize our pipeline products, our business will be materially harmed
2. 18Viatris has exclusive global rights to commercialize RYZUMVI and PS in key global markets. Viatris’ failure to timely develop or commercialize these products would have a material adverse effect on our business and operating results
3. 19Viatris may not be able to sublicense RYZUMVI or PS to one or more suitable parties outside the United States; or
4. 20If we fail to receive regulatory approval for gene therapy treatment of IRDs or any of our planned indications for our non-gene therapy product candidates or fail to develop additional product candidates, our commercial opportunity will be limited
5. 21Even if we do receive regulatory approval for, or successfully commercialize, our product candidates, they will be subject to ongoing regulatory review and critique. This ongoing review and critique may cause the loss of regulatory approval
6. 22We or others could discover that our product candidates lack sufficient efficacy, or sufficient efficacy compared to competitor products or that they cause undesirable side effects that were not previously identified, which could delay or prevent regulatory approval or commercialization
7. 23our reputation may suffer generally among both clinicians and patients
8. 24We face substantial competition and rapid technological change, which may result in others discovering, developing, or commercializing products before or more successfully than we do
9. 25We do not currently have any sales or marketing infrastructure in place and may face difficulties in establishing sales and marketing capabilities or engaging third parties to sell, market and distribute our products
10. 26the inability to obtain sufficient coverage and reimbursement from third-party payors and governmental agencies
11. 27Our future commercial success depends upon attaining significant market acceptance of our product candidates, if approved, among physicians, patients, third-party payors, and others in the medical community
12. 28limited genetic testing conducted on potential patients
13. 29If approved, our investigational products regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory pathway
14. 30Our profitability will likely depend in significant part on third-party reimbursement practices, which, if unfavorable, would harm our business
15. 31Product liability lawsuits against us, or our suppliers and manufacturers, could cause us to incur substantial liabilities and could limit commercialization of any product candidate that we may develop
16. 32the inability to take advantage of limitations on product liability lawsuits that apply to generic drug products, which could increase our exposure to liability for products deemed to be dangerous or defective
17. 33If we or our third-party manufacturers fail to comply with environmental or health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have an adverse effect on the success of our business
18. 34We have limited drug research and discovery capabilities and may need to acquire or license product candidates from third parties, raise additional capital, or shift capital resources to expand our product candidate pipeline

Risks Related to Our Financial Position and Need for Additional Capital

1. 35We have not generated significant revenue from sales of any products, expect to incur losses for the foreseeable future and may never achieve or maintain profitability
2. 36achieve market acceptance of our product candidates
3. 37We are a clinical-stage company, and our operations to date have been limited. We have not yet demonstrated our ability to manufacture a product at commercial scale or conduct sales and marketing activities necessary for successful product commercialization
4. 38Adverse developments affecting the financial services industry could negatively affect our current and projected business operations and our financial condition and results of operations
5. 39Termination of cash management arrangements and/or delays in accessing or actual loss of funds subject to cash management arrangements
6. 40We will need substantial additional capital in the future. If additional capital is not available, we will have to delay, reduce or cease operations
7. 41the costs associated with general corporate activities, such as the cost of filing, prosecuting and enforcing patent claims and making regulatory filings
8. 42Worldwide economic and social instability or adverse global economic conditions could adversely affect our revenue, financial condition, or results of operations
9. 43Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights to our technologies or product candidates

Risks Related to Government Regulation

1. 44Even if we receive marketing approval for our product candidates in the United States, we may never receive regulatory approval to market such product candidates outside of the United States
2. 45Legislative reform or changes in the regulatory environment affecting our business may increase the difficulty and cost for obtaining marketing approval of our product candidates, or otherwise affect the pricing and commercial viability of our product candidates
3. 46The biopharmaceutical and medical device industries are subject to extensive regulatory obligations and policies that may be subject to significant and abrupt change, including due to judicial challenges, election cycles, and resulting regulatory updates and changes in policy priorities
4. 47Any resulting changes in regulation may result in unexpected delays, increased costs, or other negative impacts on our business that are difficult to predict
5. 48Our employees or representatives may engage in misconduct or other improper activities, including violating applicable regulatory standards and requirements, which could significantly harm our business
6. 49disclose unauthorized activities to us
7. 50The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. If found to have improperly promoted off-label uses, we may become subject to significant liability
8. 51Changes to U.S. tax laws and state tax laws, such as those impacting our ability to use our net operating loss carryforwards and certain other tax attributes, may adversely affect our financial condition or results of operations and create the risk that we may need to adjust our accounting for these changes

Risks Related to Our Reliance on Third Parties

1. 52These factors may adversely affect the willingness or ability of third parties to conduct our clinical trials and may subject us to unexpected cost increases that are beyond our control
2. 53Further, requirements related to clinical trials continue to evolve, which may require additional oversight, greater costs, and/or delay. In 2023, the FDA published guidance documents related to informed consent and GCPs that may present additional requirements to CROs
3. 54collaborators may be unable to obtain the necessary marketing approvals; and
4. 55If we engage in additional acquisitions, in-licensing or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities and subject us to other risks
5. 56Our strategy of focusing on the cash-pay utilization for future sales of RYZUMVI may limit our ability to increase sales or achieve profitability with this product

Risks Related to Our Intellectual Property

1. 57We and our licensors have sought to protect our proprietary position by filing patent applications in the U.S. and abroad related to our novel technologies and product candidates
2. 58our commercial activities or products will not infringe upon the patents of others
3. 59If we do not obtain protection under the Hatch-Waxman Act and similar foreign legislation by extending the patent terms and obtaining data exclusivity for our product candidate, our business may be materially harmed
4. 60Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates
5. 61We may not be able to protect or practice our intellectual property rights throughout the world
6. 62We are involved in a patent litigation lawsuit with a competitor with respect to RYZUMVI® and we may become involved in additional lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time consuming, and unsuccessful
7. 63Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have an adverse effect on the success of our business
8. 64We may be subject to damages resulting from claims that our employees or consultants have wrongfully misappropriated the intellectual property of their former employers
9. 65If we are not able to adequately prevent disclosure of our trade secrets and other proprietary information, the value of any product we may pursue could be significantly diminished
10. 66Obtaining and maintaining our trademark protection depends on approval from the USPTO and other foreign government agencies, and third parties may challenge, infringe, or otherwise weaken our trademark rights
11. 67We may enter into collaborations, in-licensing arrangements, joint ventures, strategic alliances or partnerships with third parties that may not result in the development of commercially viable products or the generation of significant future revenues
12. 68the priority of invention of patented technology
13. 69Expansion through obtaining rights to product candidates and approved products through acquisitions may not be successful

Risks Related to Our Employee Matters and Managing Growth

1. 70We are dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy
2. 71We expect that we will need to develop and expand a number of corporate functions in our company (including sales, marketing, and distribution teams), and, as a result, we may encounter difficulties in managing this development and expansion, which could disrupt our operations
3. 72A variety of risks associated with operating internationally for us and our collaborators could adversely affect our business
4. 73changes in diplomatic and trade relationships; and
5. 74Our business and operations could suffer in the event of system failures or unplanned events, including cyber incidents, network security breaches, service interruptions, or data corruption

Risks Related to Ownership of Our Common Stock

1. 75The market price of our common stock is expected to be volatile
2. 76the results of clinical trials of our gene therapy products, PS, or any other product candidate that we may develop
3. 77We do not anticipate paying any cash dividends in the foreseeable future
4. 78We may be subject to securities litigation, which is expensive and could divert management attention
5. 79Actions of activist stockholders could adversely affect our business and stock price and cause us to incur significant expenses